Keely Nunnally, NP
Family · Durant, OKNPI 1356905988
Payments from drug & device makers
Across 202 payments — averaging $17.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$835
- Johnson & Johnson$385
- Merck$226
- Pfizer$178
- Otsuka America Pharmaceutical, Inc.$174
- Amgen$155
- plus $2K from 30 others
What the payments were for
- Food & beverage$3,482100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 57 | $835 |
| Johnson & Johnson | 15 | $385 |
| Merck | 16 | $226 |
| Pfizer | 11 | $178 |
| Otsuka America Pharmaceutical, Inc. | 8 | $174 |
| Amgen | 9 | $155 |
| Vivus LLC | 7 | $138 |
| Novo Nordisk | 7 | $133 |
| Exact Sciences | 8 | $122 |
| Sanofi-aventis U.S. LLC | 7 | $107 |
| AstraZeneca | 5 | $96 |
| Boehringer Ingelheim | 4 | $83 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $69 |
| Novartis | 4 | $62 |
| Lilly USA, LLC | 4 | $60 |
| Indivior Inc. | 4 | $60 |
| GSK | 3 | $45 |
| Scpharmaceuticals Inc. | 2 | $44 |
| Irhythm Technologies, Inc. | 3 | $44 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $39 |
| Impulse Dynamics (USA) Inc. | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $37 |
| Abbott | 2 | $34 |
| Lexicon Pharmaceuticals, Inc. | 2 | $32 |
| Vanda Pharmaceuticals Inc. | 1 | $31 |
| Bayer | 2 | $30 |
| Seqirus USA Inc | 1 | $30 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $30 |
| Inari Medical, Inc. | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Edwards Lifesciences | 1 | $24 |
| Boston Scientific | 1 | $24 |
| Vital Connect, Inc | 1 | $19 |
| Mylan Specialty L.p. | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Medicomp Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,482 in reported general payments places this provider in the 90th percentile of 2,026 family providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 79 | $94,923 |
| VraylarCariprazine Hcl | 44 | $62,793 |
| FarxigaDapagliflozin Propanediol | 61 | $58,120 |
| EliquisApixaban | 67 | $52,331 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $43,172 |
| LinzessLinaclotide | 49 | $35,336 |
| OzempicSemaglutide | 32 | $33,473 |
| JanuviaSitagliptin Phosphate | 29 | $31,790 |
| JardianceEmpagliflozin | 35 | $25,445 |
| XareltoRivaroxaban | 17 | $21,257 |
| TrulicityDulaglutide | 21 | $20,480 |
| Tresiba Flextouch U-100Insulin Degludec | 25 | $11,509 |
| MyrbetriqMirabegron | 15 | $11,479 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $6,748 |
| Clonidine | 20 | $2,781 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $60 | $115,403100 claims |
| AbbVieVraylar, Linzess | $835 | $98,12993 claims |
| AstraZenecaFarxiga | $96 | $58,12061 claims |
| PfizerEliquis | $178 | $52,33167 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $45 | $49,92166 claims |
| Novo NordiskOzempic | $133 | $33,47332 claims |
| MerckJanuvia | $226 | $31,79029 claims |
| Boehringer IngelheimJardiance | $83 | $25,44535 claims |
| Johnson & JohnsonXarelto | $385 | $21,25717 claims |
| Sanofi-aventis U.S. LLCLantus | $107 | $84913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,026 family providers in Oklahoma.
Other family in Durant
- April WilcoxOklahoma City$245K
- Jeremy MorganOklahoma City$63K
- Samantha BellingerOklahoma City$39K
- Candy WilliamsTulsa$22K
- Lacey HillOklahoma City$20K
- Shelby WrightStillwater$17K
- Brandy ReevesNorman$17K
- Amanda OblanderYukon$17K
- Julia John SamuelOklahoma City$17K
- Jillian OakleafTulsa$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.